Cardiol Therapeutics Inc Class A

Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-fibrotic and anti-inflammatory therapies for heart diseases. Its lead candidate, CardiolRx, is in a Phase III multinational, randomized, double-blind, placebo-controlled study for acute myocarditis and recurrent pericarditis. The company is also developing CRD-38, a subcutaneous cannabidiol formulation for heart failure. Incorporated in 2017, it is headquartered in Oakville, Canada.